p21Waf1/Cip1 as a therapeutic target in breast and other cancers.
The cyclin kinase inhibitor p21, originally described as a universal inhibitor of cyclin-dependent kinases, has since been shown to have additional functions other than CDK inhibition. It is likely that a key role of p21 is to keep cells alive after DNA damage and subsequent p53 induction, in order for the cell to effect repairs. Thus, the increase in p21 seen in some cancers may impart these cells with a survival advantage. Here we discuss how this antiapoptotic aspect of p21 makes it an attractive target for cancer therapy; attenuation of p21 in malignant cells may subvert the normal repair process induced by DNA-damaging chemotherapeutic agents and thus make such drugs more effective.
Weiss
Robert H
RH
Division of Nephrology, Department of Internal Medicine and Cancer Center University of California, Davis, California 95616, USA. rhweiss@ucdavis.edu
D001943:Breast Neoplasms / Q000378:metabolism* / Q000503:physiopathology; D002453:Cell Cycle / Q000502:physiology; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases / Q000378:metabolism; D016213:Cyclins / Q000378:metabolism*; D004249:DNA Damage / Q000502:physiology*; D004260:DNA Repair / Q000502:physiology*; D016373:DNA, Antisense / Q000378:metabolism; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D008958:Models, Molecular; D015398:Signal Transduction / Q000502:physiology; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D016373:DNA, Antisense; D016159:Tumor Suppressor Protein p53; D018844:Cyclin-Dependent Kinases